两种型号γ计数器测量正电子核素~(89)Zr的应用研究
|
摘要
目的 PE公司两种型号γ计数器测定正电子核素~(89)Zr放射性强度的应用比较。方法用PE公司2480 WIZARD2、Wallac1470 WIZARDγ计数器分别测定同一~(89)Zr样品的CPM,计算cpm均值分别建立标准曲线,对每个样品的实际测量耗时、本底计数、精密度、重现性及相对测量效率等性能指标进行比较研究。结果当2480 WIZARD2、Wallac1470 WIZARDγ计数器的测量时间均设置为12 s时,每管的实际测量耗时分别为29.5 s和13.8 s。~(89)Zr的放射性活度在37~3.7×10~5Bq范围内2种型号γ计数器测量cpm值线性关系良好,回归方程分别为:y(cpm)=227.09x(Bq),R2=1和y(cpm)=14.04x(Bq),R~2=0.9995。最低检测限均为37 Bq。在待测样品总强度达7×3.7×10~5Bq时计数~(89)Zr初次本底值(cpm)分别为4263±45和2589±240。精密度分别为:0.63和0.98。重现性试验的RSD分别为:2.51和6.33。γ计数器测量~(89)Zr的相对效率分别为:44.59%和23.21%。结论 PE公司两种型号γ计数器操作简单、准确、灵敏,适用于~(89)Zr的放射性强度测定;总体测量效果和主要性能指标2480明显优于1470。
Objective To compare the application of 2 types of γ counter~(89) Zr in the determination of the radioactive intensity of positron emission PE. Methods With PE company 2480 WIZARD2,Wallac1470 wizard γ counter samples of the same ~(89) Zr cpm were measured,cpm were calculated,respectively to establishv the standard curve. Comparison study was made for the practical measurements of each sample,the background count,precision,reproduce and relative measurement efficiency performance. Results When the measurement time of 2480 Wallac1470,WIZARD WIZARD2 γ counter was set to 12 seconds,the actual measurement time of each tube was 29. 5 and 13. 8 seconds respectively. The radioactive activity of~(89) Zr in the37 ~ 3. 7 × 10~5 Bq range two model gamma counter measurement cpm linear relationship is good. The regression equation is: y( cpm) = 227. 09x( Bq),R~2= 1 and y( cpm) = 14. 04x( Bq),R~2= 0. 9995. The lowest detection limits both were 37 Bq.The initial value of the counter~(89)Zr( cpm) was 4263 ± 45 and 2589 ± 240,respectively. When the total strength of the sample to be measured was 7 × 3. 7 × 10~5 Bq,the precision is 0. 63 and 0. 98 respectively. Reproducibility tests of RSD were: 2. 51 and 6. 33. The relative efficiencies of~(89) Zr for γ counter measurement were 44. 59% and 23. 21% respectively. Conclusion The 2 types of PE γ counter is simple,accurate and sensitive,and can be used for the determination of the radioactive intensity of~(89) Zr. The overall measurement results and most of the performance indicators 2480 are significantly better than 1470.
Objective To compare the application of 2 types of γ counter~(89) Zr in the determination of the radioactive intensity of positron emission PE. Methods With PE company 2480 WIZARD2,Wallac1470 wizard γ counter samples of the same ~(89) Zr cpm were measured,cpm were calculated,respectively to establishv the standard curve. Comparison study was made for the practical measurements of each sample,the background count,precision,reproduce and relative measurement efficiency performance. Results When the measurement time of 2480 Wallac1470,WIZARD WIZARD2 γ counter was set to 12 seconds,the actual measurement time of each tube was 29. 5 and 13. 8 seconds respectively. The radioactive activity of~(89) Zr in the37 ~ 3. 7 × 10~5 Bq range two model gamma counter measurement cpm linear relationship is good. The regression equation is: y( cpm) = 227. 09x( Bq),R~2= 1 and y( cpm) = 14. 04x( Bq),R~2= 0. 9995. The lowest detection limits both were 37 Bq.The initial value of the counter~(89)Zr( cpm) was 4263 ± 45 and 2589 ± 240,respectively. When the total strength of the sample to be measured was 7 × 3. 7 × 10~5 Bq,the precision is 0. 63 and 0. 98 respectively. Reproducibility tests of RSD were: 2. 51 and 6. 33. The relative efficiencies of~(89) Zr for γ counter measurement were 44. 59% and 23. 21% respectively. Conclusion The 2 types of PE γ counter is simple,accurate and sensitive,and can be used for the determination of the radioactive intensity of~(89) Zr. The overall measurement results and most of the performance indicators 2480 are significantly better than 1470.
引文
[1]Zhernosekov KP,Filosofov DV.Processing of Generator-Produced68Ga for Medical Application[J].J Nucl Med,2007,48:1741-1748.
[2]胡杰,汪太松,赵晋华.不同核素对GC-1500本底测定的影响[J].医疗卫生装备,2013,34(9):119-120.
[3]Holland JP,Divilov V,Bander NH,et al.Zr-DFO-J591 for immuno PET imaging of prostate-specific membrane antigen(PSMA)expression in vivo[J].Journal of Nuclear Medicine,2010,51(8):1293-300.
[4]Wooten AL,Madrid E,Schweitzer GD,et al.Routine Production of89Zr Using an Automated Module[J].Applied Sciences,2013,3(3):593-613.
[5]Muylle K,Flamen P,Vugts DJ,et al.Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by89Zr-rituximab immuno-PET:impact of preloading with unlabelled rituximab[J].European Journal of Nuclear Medicine and Molecular Imaging,2015,42(8):1-11.
[6]Yang X,Liu H,Sun CK,et al.Imaging of hepatocellular carcinoma patient-derived xenografts using 89 Zr-labeled anti-glypican-3monoclonal antibody[J].Biomaterials,2014,35(25):6964-6971.
[7]Michael G,Doran,Kathryn E.,Carnazza,Jeffrey M,Steckler,et al.Applying89Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins[J].Molecular Pharmaceutics,2016,13(2):683-688.
[8]Jason P,Holland,Vadim Divilov,Neil H.Bander,et al.89Zr-DFO-J591 for Immuno PET of Prostate-Specific Membrane Antigen Expression In Vivo[J].J Nucl Med,2010,51(8):1293-1300.
[9]Wei L,Shi J,Afari G,et al.Preparation of clinical-grade89Zrpanitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy[J].Journal of Labelled Compounds,2014,57(1):25-35.
[10]徐希杰,邹美芬,陈全成,等.2480 WIZARD2珈玛计数器测量正电子核素68Ga的应用研究[J].中国辐射卫生,2013,22(6):651-653.
[11]Natarajan A,Gambhir SS,.Radiation Dosimetry Study of[89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography[J].Molecular Imaging&Biology2015,17(4):1-9.
[12]Natarajan A,Habte F,Liu H,et al.Evaluation of89Zr-rituximab Tracer by Cerenkov Luminescence Imaging and Correlation with PETin a Humanized Transgenic Mouse Model to Image NHL[J].Molecular Imaging&Biology Mib the Official Publication of the Academy of Molecular Imaging,2013,15(4):468-475.
[13]Dijkers EC,Kosterink JG,Rademaker AP,et al.Development and characterization of clinical-grade89Zr-trastuzumab for HER2/neu immuno PET imaging[J].Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine,2009,50(6):974-981.
[2]胡杰,汪太松,赵晋华.不同核素对GC-1500本底测定的影响[J].医疗卫生装备,2013,34(9):119-120.
[3]Holland JP,Divilov V,Bander NH,et al.Zr-DFO-J591 for immuno PET imaging of prostate-specific membrane antigen(PSMA)expression in vivo[J].Journal of Nuclear Medicine,2010,51(8):1293-300.
[4]Wooten AL,Madrid E,Schweitzer GD,et al.Routine Production of89Zr Using an Automated Module[J].Applied Sciences,2013,3(3):593-613.
[5]Muylle K,Flamen P,Vugts DJ,et al.Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by89Zr-rituximab immuno-PET:impact of preloading with unlabelled rituximab[J].European Journal of Nuclear Medicine and Molecular Imaging,2015,42(8):1-11.
[6]Yang X,Liu H,Sun CK,et al.Imaging of hepatocellular carcinoma patient-derived xenografts using 89 Zr-labeled anti-glypican-3monoclonal antibody[J].Biomaterials,2014,35(25):6964-6971.
[7]Michael G,Doran,Kathryn E.,Carnazza,Jeffrey M,Steckler,et al.Applying89Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins[J].Molecular Pharmaceutics,2016,13(2):683-688.
[8]Jason P,Holland,Vadim Divilov,Neil H.Bander,et al.89Zr-DFO-J591 for Immuno PET of Prostate-Specific Membrane Antigen Expression In Vivo[J].J Nucl Med,2010,51(8):1293-1300.
[9]Wei L,Shi J,Afari G,et al.Preparation of clinical-grade89Zrpanitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy[J].Journal of Labelled Compounds,2014,57(1):25-35.
[10]徐希杰,邹美芬,陈全成,等.2480 WIZARD2珈玛计数器测量正电子核素68Ga的应用研究[J].中国辐射卫生,2013,22(6):651-653.
[11]Natarajan A,Gambhir SS,.Radiation Dosimetry Study of[89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography[J].Molecular Imaging&Biology2015,17(4):1-9.
[12]Natarajan A,Habte F,Liu H,et al.Evaluation of89Zr-rituximab Tracer by Cerenkov Luminescence Imaging and Correlation with PETin a Humanized Transgenic Mouse Model to Image NHL[J].Molecular Imaging&Biology Mib the Official Publication of the Academy of Molecular Imaging,2013,15(4):468-475.
[13]Dijkers EC,Kosterink JG,Rademaker AP,et al.Development and characterization of clinical-grade89Zr-trastuzumab for HER2/neu immuno PET imaging[J].Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine,2009,50(6):974-981.